Prevalence of multidrug-resistant tuberculosis at a regional drug-resistant tuberculosis center of Maharashtra

Introduction: Multidrug-resistant tuberculosis (MDR-TB) has created a significant health problem in most of the countries, and it is an obstacle to effective TB control. Aims and Objectives: The study aims to study the prevalence of MDR-TB among new cases, retreatment cases and to study the rate of...

Full description

Bibliographic Details
Main Authors: Gauri Suhas Kulkarni, Supriya Dhakne Palwe, Nilesh P Patil, Abhijit J Telkhade, Jui Kadukar
Format: Article
Language:English
Published: Jaypee Brothers Medical Publisher 2020-01-01
Series:Indian Journal of Respiratory Care
Subjects:
Online Access:http://www.ijrconline.org/article.asp?issn=2277-9019;year=2020;volume=9;issue=1;spage=30;epage=34;aulast=Kulkarni
_version_ 1797694431115083776
author Gauri Suhas Kulkarni
Supriya Dhakne Palwe
Nilesh P Patil
Abhijit J Telkhade
Jui Kadukar
author_facet Gauri Suhas Kulkarni
Supriya Dhakne Palwe
Nilesh P Patil
Abhijit J Telkhade
Jui Kadukar
author_sort Gauri Suhas Kulkarni
collection DOAJ
description Introduction: Multidrug-resistant tuberculosis (MDR-TB) has created a significant health problem in most of the countries, and it is an obstacle to effective TB control. Aims and Objectives: The study aims to study the prevalence of MDR-TB among new cases, retreatment cases and to study the rate of MDR-TB detection among suspected cases of Category I (CAT I) failure, CAT II failure and at the start of CAT II. Patients and Methods: The present retrolective study was conducted by reviewing the records of diagnosed MDR-TB patients at a drug-resistant TB center from January 2012 to December 2013. The data of new and retreatment pulmonary TB (PTB) cases diagnosed during that period were collected. The data were analyzed to find out the prevalence of MDR-TB, and the rate of MDR-TB detected among each CAT. Results: The prevalence of MDR-TB in new cases was 0.10% and that of retreatment cases was 4.3%. The rate of MDR-TB detection among suspected cases of CAT I failure was 16.8%, 52.4% in CAT II failure, 11.6% at the start of CAT II, 11.7% among sputum positive during any month follow-up, 6.6% among MDR-TB contacts. Conclusion: Timely suspicion and diagnosis of MDR-TB and treatment are important in new and retreatment cases. All relapse or defaulter patients should be screened for MDR-TB at the start of CAT II treatment. MDR-TB should be suspected in any sputum-positive TB patient during treatment/sputum positive relapse/defaulter PTB.
first_indexed 2024-03-12T02:57:49Z
format Article
id doaj.art-266eaacfbbb942acb3d2b04f329fd46c
institution Directory Open Access Journal
issn 2277-9019
2321-4899
language English
last_indexed 2024-03-12T02:57:49Z
publishDate 2020-01-01
publisher Jaypee Brothers Medical Publisher
record_format Article
series Indian Journal of Respiratory Care
spelling doaj.art-266eaacfbbb942acb3d2b04f329fd46c2023-09-03T15:11:38ZengJaypee Brothers Medical PublisherIndian Journal of Respiratory Care2277-90192321-48992020-01-0191303410.4103/ijrc.ijrc_10_19Prevalence of multidrug-resistant tuberculosis at a regional drug-resistant tuberculosis center of MaharashtraGauri Suhas KulkarniSupriya Dhakne PalweNilesh P PatilAbhijit J TelkhadeJui KadukarIntroduction: Multidrug-resistant tuberculosis (MDR-TB) has created a significant health problem in most of the countries, and it is an obstacle to effective TB control. Aims and Objectives: The study aims to study the prevalence of MDR-TB among new cases, retreatment cases and to study the rate of MDR-TB detection among suspected cases of Category I (CAT I) failure, CAT II failure and at the start of CAT II. Patients and Methods: The present retrolective study was conducted by reviewing the records of diagnosed MDR-TB patients at a drug-resistant TB center from January 2012 to December 2013. The data of new and retreatment pulmonary TB (PTB) cases diagnosed during that period were collected. The data were analyzed to find out the prevalence of MDR-TB, and the rate of MDR-TB detected among each CAT. Results: The prevalence of MDR-TB in new cases was 0.10% and that of retreatment cases was 4.3%. The rate of MDR-TB detection among suspected cases of CAT I failure was 16.8%, 52.4% in CAT II failure, 11.6% at the start of CAT II, 11.7% among sputum positive during any month follow-up, 6.6% among MDR-TB contacts. Conclusion: Timely suspicion and diagnosis of MDR-TB and treatment are important in new and retreatment cases. All relapse or defaulter patients should be screened for MDR-TB at the start of CAT II treatment. MDR-TB should be suspected in any sputum-positive TB patient during treatment/sputum positive relapse/defaulter PTB.http://www.ijrconline.org/article.asp?issn=2277-9019;year=2020;volume=9;issue=1;spage=30;epage=34;aulast=Kulkarniisoniazidmultidrug-resistant directly observed therapyrifampicintuberculosis
spellingShingle Gauri Suhas Kulkarni
Supriya Dhakne Palwe
Nilesh P Patil
Abhijit J Telkhade
Jui Kadukar
Prevalence of multidrug-resistant tuberculosis at a regional drug-resistant tuberculosis center of Maharashtra
Indian Journal of Respiratory Care
isoniazid
multidrug-resistant directly observed therapy
rifampicin
tuberculosis
title Prevalence of multidrug-resistant tuberculosis at a regional drug-resistant tuberculosis center of Maharashtra
title_full Prevalence of multidrug-resistant tuberculosis at a regional drug-resistant tuberculosis center of Maharashtra
title_fullStr Prevalence of multidrug-resistant tuberculosis at a regional drug-resistant tuberculosis center of Maharashtra
title_full_unstemmed Prevalence of multidrug-resistant tuberculosis at a regional drug-resistant tuberculosis center of Maharashtra
title_short Prevalence of multidrug-resistant tuberculosis at a regional drug-resistant tuberculosis center of Maharashtra
title_sort prevalence of multidrug resistant tuberculosis at a regional drug resistant tuberculosis center of maharashtra
topic isoniazid
multidrug-resistant directly observed therapy
rifampicin
tuberculosis
url http://www.ijrconline.org/article.asp?issn=2277-9019;year=2020;volume=9;issue=1;spage=30;epage=34;aulast=Kulkarni
work_keys_str_mv AT gaurisuhaskulkarni prevalenceofmultidrugresistanttuberculosisataregionaldrugresistanttuberculosiscenterofmaharashtra
AT supriyadhaknepalwe prevalenceofmultidrugresistanttuberculosisataregionaldrugresistanttuberculosiscenterofmaharashtra
AT nileshppatil prevalenceofmultidrugresistanttuberculosisataregionaldrugresistanttuberculosiscenterofmaharashtra
AT abhijitjtelkhade prevalenceofmultidrugresistanttuberculosisataregionaldrugresistanttuberculosiscenterofmaharashtra
AT juikadukar prevalenceofmultidrugresistanttuberculosisataregionaldrugresistanttuberculosiscenterofmaharashtra